Clinical Trial Detail

NCT ID NCT02302339
Title A Study of Glembatumumab Vedotin in Patients With Advanced Melanoma
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Celldex Therapeutics
Indications

melanoma

Therapies

Glembatumumab vedotin

Age Groups: adult

No variant requirements are available.